Price (delayed)
$0.5058
Market cap
$48.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.61
Enterprise value
$33.15M
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of
There are no recent dividends present for CRIS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.